What is Leerink Partnrs’ Forecast for ABVX FY2024 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX) – Investment analysts at Leerink Partnrs dropped their FY2024 earnings estimates for ABIVAX Société Anonyme in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.08) per share for the year, down from their prior forecast of ($2.93). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.09) EPS and FY2028 earnings at ($0.84) EPS.

A number of other equities research analysts have also recently issued reports on ABVX. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of “Buy” and an average price target of $38.00.

ABIVAX Société Anonyme Stock Up 4.5 %

ABVX stock opened at $7.38 on Thursday. The company has a fifty day moving average price of $6.73 and a two-hundred day moving average price of $8.55. ABIVAX Société Anonyme has a one year low of $5.50 and a one year high of $16.63.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP bought a new stake in ABIVAX Société Anonyme during the fourth quarter worth about $144,000. Stonepine Capital Management LLC bought a new stake in ABIVAX Société Anonyme during the fourth quarter worth about $110,000. Shay Capital LLC bought a new stake in ABIVAX Société Anonyme during the fourth quarter worth about $366,000. Millennium Management LLC lifted its position in ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock worth $6,816,000 after purchasing an additional 285,542 shares during the period. Finally, Citadel Advisors LLC lifted its position in ABIVAX Société Anonyme by 83.5% during the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock worth $6,264,000 after purchasing an additional 389,247 shares during the period. Institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.